Climb Bio Inc - Asset Resilience Ratio
Climb Bio Inc (CLYM) has an Asset Resilience Ratio of 66.42% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Climb Bio Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Climb Bio Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Climb Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Climb Bio Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $101.21 Million | 66.42% |
| Total Liquid Assets | $101.21 Million | 66.42% |
Asset Resilience Insights
- Very High Liquidity: Climb Bio Inc maintains exceptional liquid asset reserves at 66.42% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Climb Bio Inc Industry Peers by Asset Resilience Ratio
Compare Climb Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Climb Bio Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Climb Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 38.99% | $65.39 Million | $167.74 Million | +9.66pp |
| 2024-12-31 | 29.32% | $63.69 Million | $217.19 Million | +16.94pp |
| 2023-12-31 | 12.39% | $13.69 Million | $110.47 Million | -46.86pp |
| 2022-12-31 | 59.25% | $79.98 Million | $134.99 Million | +7.55pp |
| 2021-12-31 | 51.70% | $89.56 Million | $173.24 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $24.63 Million | -- |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary me… Read more